Lv7
3370 积分 2023-08-02 加入
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
28天前
已完结
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study
28天前
已完结
Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning
28天前
已完结
Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro
29天前
已完结
SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study
1个月前
已完结
2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
2个月前
已完结
Asundexian for Secondary Stroke Prevention
4个月前
已完结
Asundexian for Secondary Stroke Prevention
4个月前
已完结
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
6个月前
已关闭
皖公网安备34019202002308
